Drug Trial Radar · NCT05705505
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 29, 2023
Primary completion
Jan 2026
Study completion Feb 2026
Sponsor
- Lead sponsor
- Traws Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of increasing doses of narazaciclib (ON 123300) in combination with the standard daily dose (2.5mg) of letrozole in patients with Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer and other Gynecologic Malignancies.
Conditions
- Endometrioid Endometrial Cancer
Interventions
NarazaciclibDrug
Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
Letrozole 2.5mgDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLTs) will be tabulated and summarized by cohortTime frame: From First dose until end of Cycle 1 (28 days)
- Treatment-emergent adverse events (TEAEs), including DLTs will be graded by CTCAE v5.0Time frame: From first dose until 30 days after final dose, up to approximately 1 year
- Phase 2 - Progression-free survival (PFS) at 24 weeks by Investigator assessmentTime frame: Measured from first dose until 24-weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona · Recruiting
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota · Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
NYU Langone
New York, New York · Recruiting
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon · Recruiting
Greenville Health System, Institute for Oncology Clinical Research
Greenville, South Carolina · Recruiting
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas · Recruiting
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.